Annual report pursuant to Section 13 and 15(d)

Note 3 - Discontinued Operations - Discontinued Operations (Details)

v3.8.0.1
Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net       $ 1,598,994       $ 1,598,994  
Disposal Group, Including Discontinued Operation, Inventory       1,374,618       1,374,618  
Prepaid expenses       170,635       170,635  
Assets associated with discontinued operations, current       3,144,247       3,144,247  
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent       70,973       70,973  
Patents and trademarks, net of accumulated amortization       34,282       34,282  
Assets associated with discontinued operations, noncurrent       105,255       105,255  
Total assets associated with discontinued operations       3,249,502       3,249,502  
Disposal Group, Including Discontinued Operation, Accounts Payable, Current       1,957,938       1,957,938  
Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current 7,092       607,659       7,092 607,659  
Deferred revenue       2,300,000       2,300,000  
Liabilities associated with discontinued operations, current 7,092       4,865,597       7,092 4,865,597  
Other liabilities              
Total liabilities associated with discontinued operations 7,092       4,865,597       7,092 4,865,597  
Lymphoseek sales revenue                 2,917,213 16,997,497 $ 10,235,277
Disposa Group, Including Discontinued Operation, Royalty Revenue                 1,194,660
Grant and other revenue                   575 669
Total revenue                 2,917,213 16,998,072 11,430,606
Cost of goods sold                 364,192 2,234,780 1,751,537
Gross profit                 2,553,021 14,763,292 9,679,069
Research and development                 383,446 1,744,496 2,225,004
Selling, general and administrative                 961,873 5,093,529 6,369,183
Total operating expenses                 1,345,319 6,838,025 8,594,187
Income from discontinued operations                 1,207,702 7,925,267 1,084,882
Interest expense                 (1,706,491) (14,856,404) (5,603,820)
Income (loss) before income taxes                 (498,789) (6,931,137) (4,518,938)
Benefit from (provision for) income taxes                 8,031
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax $ 2,112,000 $ 151,000 $ (2,036,000) $ 88,446,000 $ (1,764,000) $ 1,702,000 $ (5,865,000) $ (1,004,000) $ (490,758) $ (6,931,137) $ (4,518,938) [1]
[1] Amount not allocated to a reportable segment represents contingent consideration recognized related to 2015 GDS Business revenue royalties pursuant to the 2011 sale of the GDS Business to Devicor, net of tax effect. See Note 1(a).